Search

Your search keyword '"AstraZeneca PLC -- Product development"' showing total 429 results

Search Constraints

Start Over You searched for: Descriptor "AstraZeneca PLC -- Product development" Remove constraint Descriptor: "AstraZeneca PLC -- Product development" Search Limiters Full Text Remove constraint Search Limiters: Full Text
429 results on '"AstraZeneca PLC -- Product development"'

Search Results

1. FDA approves first nasal spray flu vaccine for use at home

2. FDA approves first nasal spray flu vaccine for use at home

3. New COVID-19 Study Findings Have Been Reported from University of Texas MD Anderson Cancer Center [Acalabrutinib In Combination With Rituximab and Lenalidomide In Patients With Relapsed or Refractory Follicular Lymphoma: Results of the Phase 1b ...]

4. AstraZeneca drug for early lung cancer fails Phase 3 trial

5. eSource Interoperability Between EHR and EDC: Evidence from a Phase III cancer trial points to notable advances in data-transfer tech

6. Studies in the Area of Cervical Cancer Reported from University of Arizona [Durvalumab Versus Placebo With Chemoradiotherapy for Locally Advanced Cervical Cancer (Calla): a Randomised, Double-blind, Phase 3 Trial]

7. DHT RAMP-UP: PHARMA STEPS UP PURSUITS IN DIGITAL TECHNOLOGY

8. Reports Outline Clinical Trials and Studies Study Findings from AstraZeneca (Robustness Assessment of Oncology Dose-Finding Trials Using the Modified Fragility Index)

9. Findings on Respiratory Syncytial Viruses Reported by Investigators at AstraZeneca [Molecular and Phenotypic Characteristics of Respiratory Syncytial Virus Isolates Recovered From Medically Vulnerable Children: an Exploratory Analysis of a Phase ...]

10. United Kingdom : Clinical trials for chronic kidney disease

11. Reports from Tisch Cancer Institute Describe Recent Advances in Metastatic Breast Cancer (Results of a Phase Ib Study Investigating Durvalumab In Combination With Eribulin In Patients With Her2-negative Metastatic Breast Cancer and Recurrent ...)

12. Institute Curie Researchers Provide New Data on Cervical Cancer (Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial)

13. Looking beyond COVID-19 vaccine phase 3 trials

14. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

15. Recent Studies from AstraZeneca Add New Data to Breast Cancer (Design of Serena-6, a Phase Iii Switching Trial of Camizestrant In Esr1-mutant Breast Cancer During First-line Treatment)

16. New COVID-19 vaccines are in late-stage trials: For now, only the Pfizer and Moderna vaccines have full FDA approval, but many candidates are in phase 2 or 3 trials

17. Researchers at University Lyon 1 Zero in on Ovarian Cancer (Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group)

18. Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® fulvestrant in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer

19. F.D.A. Panel Supports R.S.V. Shot For Infants

20. Researcher from AstraZeneca Discusses Findings in Data Structures (Basic Data Structure for Hierarchical Composite Endpoints: An Application to Kidney Disease Trials)

21. Research from AstraZeneca Yields New Study Findings on Clinical Trials and Studies (Algorithmic benchmark modulation: A novel method to develop success rates for clinical studies)

22. Advances in eSource Interoperability Between EHR and EDC: How a study evaluating the technological capabilities to transfer data between the two sources supports the case for clinical trial transformation

23. Investigators at AstraZeneca Describe Findings in Gynecologic Oncology (Concordance of Brca Mutation Detection In Tumor Versus Blood, and Frequency of Bi-allelic Loss of Brca In Tumors From Patients In the Phase Iii Solo2 Trial)

24. From Randomized Controlled Trials to the Real World: Putting Evidence into Context

25. Research on Clinical Trials and Studies Discussed by Researchers at Hospital Bicetre (Carbon footprint of industry-sponsored late-stage clinical trials)

26. Investigators at Princess Margaret Cancer Centre Detail Findings in Ovarian Cancer (Evolve: a Multicenter Open-label Single-arm Clinical and Translational Phase Ii Trial of Cediranib Plus Olaparib for Ovarian Cancer After Parp Inhibition ...)

27. Findings from National Cancer Institute (NCI) in the Area of Ovarian Cancer Described (Combination of Parp Inhibitor Olaparib, and Pd-l1 Inhibitor Durvalumab, In Recurrent Ovarian Cancer: a Proof-of-concept Phase Ii Study)

28. United Kingdom : Update on PEARL Phase III trial of Imfinzi monotherapy in Stage IV non-small cell lung cancer

29. United Kingdom : Datopotamab deruxtecan showed promising responses as monotherapy and in combination with Imfinzi in patients with metastatic triple-negative breast cancer in two early trials

30. Trial of New Breast Cancer Drug Results in 'Unheard-Of' Survival Rates

31. Breast-cancer drug could open up new treatment possibilities: researchers

32. USING SOLID ENDPOINT STRATEGIES FOR SUCCESSFUL CANCER TRIALS

34. Now for the rocket boosters; Covid-19 vaccines

37. Another covid-19 vaccine joins the party; The coronavirus pandemic

38. Emergency exit; Covid-19 vaccines

39. Findings from Princess Margaret Cancer Centre Broadens Understanding of Ovarian Cancer [A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant ...]

40. Trials of a vaccine and new drug raise hope of beating covid-19

41. Oxford University is leading in the vaccine race

42. LYNPARZA® Olaparib Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

43. United Kingdom : Camizestrant significantly improved progression-free survival vs. Faslodex in SERENA-2 Phase II trial in advanced ER-positive breast cancer

44. United Kingdom : Update on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis

45. United Kingdom : Capivasertib plus Faslodex significantly improved progression-free survival vs. Faslodex in CAPItello-291 Phase III trial in advanced HR-positive breast cancer

46. United States : LYNPARZA (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials

47. Taiwan’s vaccine gets nod for use in Paraguay; Trials show patients generated 3.7 times as many antibodies as AstraZeneca shot

48. AstraZeneca and Oxford making version of coronavirus vaccine that targets omicron

49. Regeneron and AstraZeneca give mixed results on potency of coronavirus antibody cocktails against omicron

Catalog

Books, media, physical & digital resources